Collect

Formalin fixed paraffin embedded (FFPE) tissue block, or 5 Unstained slides - 10µm thick with ≥30% tumor (with one adjacent H&E).  This assay requires more tissue than the Solid Tumor Precision Panel (STPP) and small biopsies may not provide adequate nucleic acid.  In such cases, the STPP should be considered.

Unacceptable Conditions

  • Tissue with <20% tumor after macrodissection.
  • Tissue fixed in heavy metal fixative or decalcified tissue.
  • Fresh tissue including Blood/Bone Marrow are not accepted at this time.

Storage/Transport Temperature

Ambient Temperature

Performed

Molecular Diagnostics

Notes

This test uses Next Generation Sequencing to analyze 337 genes for targetable pathogenic variants, structural changes (including gene fusions) or copy number alterations in formalin-fixed, paraffin embedded (FFPE) solid tumor tissue specimens. Testing is performed on the Illumina NextSeq 550Dx instrument using the TruSight Oncology 500 Assay. The purpose of this test is to assist in the treatment of various solid tumors, including enrollment into clinical trials.  
Lists of assessed genes and limit of detection for each variant type are listed below in Tables 1 and 2, respectively.
Table 1. Genes Assessed
DNA - SNVs/Indels (322) (Total with CNV and RNA only genes = 337 genes)
ABL1 CCND1 ERBB2 FH JUN MYB PIK3R3 RICTOR TRAF7
ABL2 CCND2 ERBB3 FLCN KDM5A MYC PLCG2 RIT1 TSC1
ACVR1 CCND3 ERBB4 FLT1 KDM5C MYCL1 PMS1 RNF43 TSC2
ACVR1B CCNE1 ERCC1 FLT3 KDM6A MYCN PMS2 ROS1 U2AF1
AKT1 CD274 ERCC2 FLT4 KDR MYD88 POLD1 RPTOR VEGFA
AKT2 CD276 ERCC3 FOXA1 KEAP1 MYOD1 POLE RUNX1 VHL
AKT3 CDH1 ERCC4 FOXL2 KIT NAB2 PPARG RUNX1T1 WT1
ALK CDK12 ERCC5 FOXO1 KLF4 NBN PPM1D SDHA XRCC2
APC CDK4 ESR1 FUBP1 KRAS NF1 PPP2R1A SDHAF2 YAP1
AR CDK6 ETV6 GATA3 LATS2 NF2 PPP2R2A SDHB ZRSR2
ARAF CDK8 EWSR1 GEN1 LRP1B NFE2L2 PPP6C SDHC  
ARID1A CDKN1A EZH2 GLI1 LZTR1 NKX2-1 PREX2 SDHD  
ARID1B CDKN1B FAM175A GNA11 MAGI2 NOTCH1 PRKAR1A SETBP1  
ARID2 CDKN2A FANCA GNAQ MAP2K1 NOTCH2 PRKCI SETD2  
ASXL1 CDKN2B FANCC GNAS MAP2K2 NOTCH3 PRKDC SF3B1  
ASXL2 CDKN2C FANCD2 GPS2 MAP2K4 NOTCH4 PTCH1 SLX4  
ATM CHD4 FANCE H3F3A MAP3K1 NPM1 PTEN SMAD4  
ATR CHEK1 FANCF H3F3B MAP3K13 NRAS PTPN11 SMARCA4  
ATRX CHEK2 FANCG H3F3C MAP3K14 NRG1 PTPRD SMARCB1  
AXL CIC FANCI HGF MAP3K4 NSD1 PTPRS SMO  
B2M CREBBP FANCL HIST1H1C MAPK1 NTRK1 PTPRT SNCAIP  
BAP1 CRKL FBXW7 HIST1H3B MAPK3 NTRK2 QKI SPOP  
BARD1 CRLF2 FGF1 HIST1H3C MAX NTRK3 RAC1 SRC  
BCL2 CSF1R FGF10 HOXB13 MDC1 PALB2 RAD21 SRSF2  
BCL2L11 CSF3R FGF14 HRAS MDM2 PARP1 RAD50 STAG2  
BCL6 CTNNA1 FGF19 HSD3B1 MDM4 PAX8 RAD51 STAT3  
BCOR CTNNB1 FGF2 IDH1 MED12 PBRM1 RAD51B STK11  
BCORL1 DAXX FGF23 IDH2 MEN1 PDGFRA RAD51C SUFU  
BCR DDR2 FGF3 IGF1R MET PDGFRB RAD51D SUZ12  
BLM DICER1 FGF4 IKBKE MITF PHOX2B RAD52 TCEB1  
BMPR1A DNAJB1 FGF5 IL7R MLH1 PIK3C2B RAD54L TERT  
BRAF DNMT3A FGF6 INPP4A MPL PIK3C2G RAF1 TET1  
BRCA1 DNMT3B FGF7 INPP4B MRE11A PIK3C3 RASA1 TET2  
BRCA2 DOT1L FGF8 IRF2 MSH2 PIK3CA RB1 TFE3  
BRD4 EGFR FGF9 IRF4 MSH3 PIK3CB RBM10 TGFBR2  
BRIP1 EIF1AX FGFR1 IRS2 MSH6 PIK3CD RECQL4 TMEM127  
C11orf30 EML4 FGFR2 JAK1 MST1R PIK3CG RET TMPRSS2  
CALR EP300 FGFR3 JAK2 MTOR PIK3R1 RHEB TP53  
CBL EPCAM FGFR4 JAK3 MUTYH PIK3R2 RHOA TRAF2  
                 
CNV - All (59) Green=Unique   RNA - All (55)   Blue=Unique        
AKT2 FGF7   ABL1 JAK2        
ALK FGF8   AKT3 KDR        
AR FGF9   ALK KIF5B        
ATM FGFR1   AR KIT        
BRAF FGFR2   AXL MET        
BRCA1 FGFR3   BCL2 MLL        
BRCA2 FGFR4   BRAF MLLT3        
CCND1 JAK2   BRCA1 MSH2        
CCND3 KIT   BRCA2 MYC        
CCNE1 KRAS   CDK4 NOTCH1        
CDK4 LAMP1   CSF1R NOTCH2        
CDK6 MDM2   EGFR NOTCH3        
CHEK1 MDM4   EML4 NRG1        
CHEK2 MET   ERBB2 NTRK1        
EGFR MYC   ERG NTRK2        
ERBB2 MYCL1   ESR1 NTRK3        
ERBB3 MYCN   ETS1 PAX3        
ERCC1 NRAS   ETV1 PAX7        
ERCC2 NRG1   ETV4 PDGFRA        
ESR1 PDGFRA   ETV5 PDGFRB        
FGF1 PDGFRB   EWSR1 PIK3CA        
FGF10 PIK3CA   FGFR1 PPARG        
FGF14 PIK3CB   FGFR2 RAF1        
FGF19 PTEN   FGFR3 RET        
FGF2 RAF1   FGFR4 ROS1        
FGF23 RET   FLI1 RPS6KB1        
FGF3 RICTOR   FLT1 TMPRSS2        
FGF4 RPS6KB1   FLT3          
FGF5 TFRC              
FGF6                

Table 2. Limit of Detection for Variant Types
Variant Type Limit of Detection
Single Nucleotide Variants  5% variant allele fraction*, 10-20% Tumor Cellularity
Indels up to 15bp  5-10% variant allele fraction*, 10-20% Tumor Cellularity
Indels up to 30bp  30-80% Tumor Cellularity
Copy Number Amplifications  10% Tumor Cellularity/Fold Difference >2
Tumor Mutation Burden  20% Tumor Cellularity
Microsatellite Instability  30% Tumor Cellularity
Intergenetic and Intragenetic Fusions  10% Tumor Cellularity
*Certain driver or resistance variants may be reported to lower VAFs when technically possible.

Performed

Molecular Diagnostics

Methodology

The POP300 is a hybrid capture enrichment-based approach to create libraries, enriched for cancer-related genes, from DNA and RNA, extracted from formalin-fixed paraffin embedded (FFPE) tissue specimens.   Libraries are sequenced on the Illumina® NextSeq 550 Dx Next Generation Sequencer.  DNA-derived biomarkers include the following: single nucleotide variants (SNVs), insertions, deletions, gene amplifications, multi-nucleotide variants (MNVs), and the immunotherapy biomarkers tumor mutational burden (TMB) and microsatellite instability (MSI).  Fusions and splice variants are detected using extracted RNA.  Copy number loss is not validated at this time, and FISH is recommended to identify loss of CDKN2A and PTEN.  Immunohistochemistry is recommended to assess endometrial adenocarcinomas for mismatch repair deficiency (PMID: 36603179). Reporting will be performed using GenomOncology (GO) software.  Human genome reference 19 (hg19) is used for alignment and variant calling. 

Lists of assessed genes and limit of detection for each variant type are listed below in Tables 1 and 2, respectively.
Table 1. Genes Assessed
DNA - SNVs/Indels (322) (Total with CNV and RNA only genes = 337 genes)
ABL1 CCND1 ERBB2 FH JUN MYB PIK3R3 RICTOR TRAF7
ABL2 CCND2 ERBB3 FLCN KDM5A MYC PLCG2 RIT1 TSC1
ACVR1 CCND3 ERBB4 FLT1 KDM5C MYCL1 PMS1 RNF43 TSC2
ACVR1B CCNE1 ERCC1 FLT3 KDM6A MYCN PMS2 ROS1 U2AF1
AKT1 CD274 ERCC2 FLT4 KDR MYD88 POLD1 RPTOR VEGFA
AKT2 CD276 ERCC3 FOXA1 KEAP1 MYOD1 POLE RUNX1 VHL
AKT3 CDH1 ERCC4 FOXL2 KIT NAB2 PPARG RUNX1T1 WT1
ALK CDK12 ERCC5 FOXO1 KLF4 NBN PPM1D SDHA XRCC2
APC CDK4 ESR1 FUBP1 KRAS NF1 PPP2R1A SDHAF2 YAP1
AR CDK6 ETV6 GATA3 LATS2 NF2 PPP2R2A SDHB ZRSR2
ARAF CDK8 EWSR1 GEN1 LRP1B NFE2L2 PPP6C SDHC  
ARID1A CDKN1A EZH2 GLI1 LZTR1 NKX2-1 PREX2 SDHD  
ARID1B CDKN1B FAM175A GNA11 MAGI2 NOTCH1 PRKAR1A SETBP1  
ARID2 CDKN2A FANCA GNAQ MAP2K1 NOTCH2 PRKCI SETD2  
ASXL1 CDKN2B FANCC GNAS MAP2K2 NOTCH3 PRKDC SF3B1  
ASXL2 CDKN2C FANCD2 GPS2 MAP2K4 NOTCH4 PTCH1 SLX4  
ATM CHD4 FANCE H3F3A MAP3K1 NPM1 PTEN SMAD4  
ATR CHEK1 FANCF H3F3B MAP3K13 NRAS PTPN11 SMARCA4  
ATRX CHEK2 FANCG H3F3C MAP3K14 NRG1 PTPRD SMARCB1  
AXL CIC FANCI HGF MAP3K4 NSD1 PTPRS SMO  
B2M CREBBP FANCL HIST1H1C MAPK1 NTRK1 PTPRT SNCAIP  
BAP1 CRKL FBXW7 HIST1H3B MAPK3 NTRK2 QKI SPOP  
BARD1 CRLF2 FGF1 HIST1H3C MAX NTRK3 RAC1 SRC  
BCL2 CSF1R FGF10 HOXB13 MDC1 PALB2 RAD21 SRSF2  
BCL2L11 CSF3R FGF14 HRAS MDM2 PARP1 RAD50 STAG2  
BCL6 CTNNA1 FGF19 HSD3B1 MDM4 PAX8 RAD51 STAT3  
BCOR CTNNB1 FGF2 IDH1 MED12 PBRM1 RAD51B STK11  
BCORL1 DAXX FGF23 IDH2 MEN1 PDGFRA RAD51C SUFU  
BCR DDR2 FGF3 IGF1R MET PDGFRB RAD51D SUZ12  
BLM DICER1 FGF4 IKBKE MITF PHOX2B RAD52 TCEB1  
BMPR1A DNAJB1 FGF5 IL7R MLH1 PIK3C2B RAD54L TERT  
BRAF DNMT3A FGF6 INPP4A MPL PIK3C2G RAF1 TET1  
BRCA1 DNMT3B FGF7 INPP4B MRE11A PIK3C3 RASA1 TET2  
BRCA2 DOT1L FGF8 IRF2 MSH2 PIK3CA RB1 TFE3  
BRD4 EGFR FGF9 IRF4 MSH3 PIK3CB RBM10 TGFBR2  
BRIP1 EIF1AX FGFR1 IRS2 MSH6 PIK3CD RECQL4 TMEM127  
C11orf30 EML4 FGFR2 JAK1 MST1R PIK3CG RET TMPRSS2  
CALR EP300 FGFR3 JAK2 MTOR PIK3R1 RHEB TP53  
CBL EPCAM FGFR4 JAK3 MUTYH PIK3R2 RHOA TRAF2  
                 
CNV - All (59) Green=Unique   RNA - All (55)   Blue=Unique        
AKT2 FGF7   ABL1 JAK2        
ALK FGF8   AKT3 KDR        
AR FGF9   ALK KIF5B        
ATM FGFR1   AR KIT        
BRAF FGFR2   AXL MET        
BRCA1 FGFR3   BCL2 MLL        
BRCA2 FGFR4   BRAF MLLT3        
CCND1 JAK2   BRCA1 MSH2        
CCND3 KIT   BRCA2 MYC        
CCNE1 KRAS   CDK4 NOTCH1        
CDK4 LAMP1   CSF1R NOTCH2        
CDK6 MDM2   EGFR NOTCH3        
CHEK1 MDM4   EML4 NRG1        
CHEK2 MET   ERBB2 NTRK1        
EGFR MYC   ERG NTRK2        
ERBB2 MYCL1   ESR1 NTRK3        
ERBB3 MYCN   ETS1 PAX3        
ERCC1 NRAS   ETV1 PAX7        
ERCC2 NRG1   ETV4 PDGFRA        
ESR1 PDGFRA   ETV5 PDGFRB        
FGF1 PDGFRB   EWSR1 PIK3CA        
FGF10 PIK3CA   FGFR1 PPARG        
FGF14 PIK3CB   FGFR2 RAF1        
FGF19 PTEN   FGFR3 RET        
FGF2 RAF1   FGFR4 ROS1        
FGF23 RET   FLI1 RPS6KB1        
FGF3 RICTOR   FLT1 TMPRSS2        
FGF4 RPS6KB1   FLT3          
FGF5 TFRC              
FGF6                

Table 2. Limit of Detection for Variant Types
Variant Type Limit of Detection
Single Nucleotide Variants  5% variant allele fraction*, 10-20% Tumor Cellularity
Indels up to 15bp  5-10% variant allele fraction*, 10-20% Tumor Cellularity
Indels up to 30bp  30-80% Tumor Cellularity
Copy Number Amplifications  10% Tumor Cellularity/Fold Difference >2
Tumor Mutation Burden  20% Tumor Cellularity
Microsatellite Instability  30% Tumor Cellularity
Intergenetic and Intragenetic Fusions  10% Tumor Cellularity
*Certain driver or resistance variants may be reported to lower VAFs when technically possible.

Synonyms

  • Comprehensive Gene Panel
  • Ovarian
  • Endometrial
  • Breast Cancer
  • Prostate Cancer
  • Bladder Cancer

CPT Codes

81455
UHC reference code:  56200053
Medicare only CPT 81479
*This test will either require prior authorization or a signed ABN

Test Build Information

Order Code Order Name Result Code Result Name CPT
POP300 Precision Oncology Profile 300 POP300R Precision Oncology Profile 300 81455
Collection

Collect

Formalin fixed paraffin embedded (FFPE) tissue block, or 5 Unstained slides - 10µm thick with ≥30% tumor (with one adjacent H&E).  This assay requires more tissue than the Solid Tumor Precision Panel (STPP) and small biopsies may not provide adequate nucleic acid.  In such cases, the STPP should be considered.

Unacceptable Conditions

  • Tissue with <20% tumor after macrodissection.
  • Tissue fixed in heavy metal fixative or decalcified tissue.
  • Fresh tissue including Blood/Bone Marrow are not accepted at this time.

Storage/Transport Temperature

Ambient Temperature

Performed

Molecular Diagnostics

Notes

This test uses Next Generation Sequencing to analyze 337 genes for targetable pathogenic variants, structural changes (including gene fusions) or copy number alterations in formalin-fixed, paraffin embedded (FFPE) solid tumor tissue specimens. Testing is performed on the Illumina NextSeq 550Dx instrument using the TruSight Oncology 500 Assay. The purpose of this test is to assist in the treatment of various solid tumors, including enrollment into clinical trials.  
Lists of assessed genes and limit of detection for each variant type are listed below in Tables 1 and 2, respectively.
Table 1. Genes Assessed
DNA - SNVs/Indels (322) (Total with CNV and RNA only genes = 337 genes)
ABL1 CCND1 ERBB2 FH JUN MYB PIK3R3 RICTOR TRAF7
ABL2 CCND2 ERBB3 FLCN KDM5A MYC PLCG2 RIT1 TSC1
ACVR1 CCND3 ERBB4 FLT1 KDM5C MYCL1 PMS1 RNF43 TSC2
ACVR1B CCNE1 ERCC1 FLT3 KDM6A MYCN PMS2 ROS1 U2AF1
AKT1 CD274 ERCC2 FLT4 KDR MYD88 POLD1 RPTOR VEGFA
AKT2 CD276 ERCC3 FOXA1 KEAP1 MYOD1 POLE RUNX1 VHL
AKT3 CDH1 ERCC4 FOXL2 KIT NAB2 PPARG RUNX1T1 WT1
ALK CDK12 ERCC5 FOXO1 KLF4 NBN PPM1D SDHA XRCC2
APC CDK4 ESR1 FUBP1 KRAS NF1 PPP2R1A SDHAF2 YAP1
AR CDK6 ETV6 GATA3 LATS2 NF2 PPP2R2A SDHB ZRSR2
ARAF CDK8 EWSR1 GEN1 LRP1B NFE2L2 PPP6C SDHC  
ARID1A CDKN1A EZH2 GLI1 LZTR1 NKX2-1 PREX2 SDHD  
ARID1B CDKN1B FAM175A GNA11 MAGI2 NOTCH1 PRKAR1A SETBP1  
ARID2 CDKN2A FANCA GNAQ MAP2K1 NOTCH2 PRKCI SETD2  
ASXL1 CDKN2B FANCC GNAS MAP2K2 NOTCH3 PRKDC SF3B1  
ASXL2 CDKN2C FANCD2 GPS2 MAP2K4 NOTCH4 PTCH1 SLX4  
ATM CHD4 FANCE H3F3A MAP3K1 NPM1 PTEN SMAD4  
ATR CHEK1 FANCF H3F3B MAP3K13 NRAS PTPN11 SMARCA4  
ATRX CHEK2 FANCG H3F3C MAP3K14 NRG1 PTPRD SMARCB1  
AXL CIC FANCI HGF MAP3K4 NSD1 PTPRS SMO  
B2M CREBBP FANCL HIST1H1C MAPK1 NTRK1 PTPRT SNCAIP  
BAP1 CRKL FBXW7 HIST1H3B MAPK3 NTRK2 QKI SPOP  
BARD1 CRLF2 FGF1 HIST1H3C MAX NTRK3 RAC1 SRC  
BCL2 CSF1R FGF10 HOXB13 MDC1 PALB2 RAD21 SRSF2  
BCL2L11 CSF3R FGF14 HRAS MDM2 PARP1 RAD50 STAG2  
BCL6 CTNNA1 FGF19 HSD3B1 MDM4 PAX8 RAD51 STAT3  
BCOR CTNNB1 FGF2 IDH1 MED12 PBRM1 RAD51B STK11  
BCORL1 DAXX FGF23 IDH2 MEN1 PDGFRA RAD51C SUFU  
BCR DDR2 FGF3 IGF1R MET PDGFRB RAD51D SUZ12  
BLM DICER1 FGF4 IKBKE MITF PHOX2B RAD52 TCEB1  
BMPR1A DNAJB1 FGF5 IL7R MLH1 PIK3C2B RAD54L TERT  
BRAF DNMT3A FGF6 INPP4A MPL PIK3C2G RAF1 TET1  
BRCA1 DNMT3B FGF7 INPP4B MRE11A PIK3C3 RASA1 TET2  
BRCA2 DOT1L FGF8 IRF2 MSH2 PIK3CA RB1 TFE3  
BRD4 EGFR FGF9 IRF4 MSH3 PIK3CB RBM10 TGFBR2  
BRIP1 EIF1AX FGFR1 IRS2 MSH6 PIK3CD RECQL4 TMEM127  
C11orf30 EML4 FGFR2 JAK1 MST1R PIK3CG RET TMPRSS2  
CALR EP300 FGFR3 JAK2 MTOR PIK3R1 RHEB TP53  
CBL EPCAM FGFR4 JAK3 MUTYH PIK3R2 RHOA TRAF2  
                 
CNV - All (59) Green=Unique   RNA - All (55)   Blue=Unique        
AKT2 FGF7   ABL1 JAK2        
ALK FGF8   AKT3 KDR        
AR FGF9   ALK KIF5B        
ATM FGFR1   AR KIT        
BRAF FGFR2   AXL MET        
BRCA1 FGFR3   BCL2 MLL        
BRCA2 FGFR4   BRAF MLLT3        
CCND1 JAK2   BRCA1 MSH2        
CCND3 KIT   BRCA2 MYC        
CCNE1 KRAS   CDK4 NOTCH1        
CDK4 LAMP1   CSF1R NOTCH2        
CDK6 MDM2   EGFR NOTCH3        
CHEK1 MDM4   EML4 NRG1        
CHEK2 MET   ERBB2 NTRK1        
EGFR MYC   ERG NTRK2        
ERBB2 MYCL1   ESR1 NTRK3        
ERBB3 MYCN   ETS1 PAX3        
ERCC1 NRAS   ETV1 PAX7        
ERCC2 NRG1   ETV4 PDGFRA        
ESR1 PDGFRA   ETV5 PDGFRB        
FGF1 PDGFRB   EWSR1 PIK3CA        
FGF10 PIK3CA   FGFR1 PPARG        
FGF14 PIK3CB   FGFR2 RAF1        
FGF19 PTEN   FGFR3 RET        
FGF2 RAF1   FGFR4 ROS1        
FGF23 RET   FLI1 RPS6KB1        
FGF3 RICTOR   FLT1 TMPRSS2        
FGF4 RPS6KB1   FLT3          
FGF5 TFRC              
FGF6                

Table 2. Limit of Detection for Variant Types
Variant Type Limit of Detection
Single Nucleotide Variants  5% variant allele fraction*, 10-20% Tumor Cellularity
Indels up to 15bp  5-10% variant allele fraction*, 10-20% Tumor Cellularity
Indels up to 30bp  30-80% Tumor Cellularity
Copy Number Amplifications  10% Tumor Cellularity/Fold Difference >2
Tumor Mutation Burden  20% Tumor Cellularity
Microsatellite Instability  30% Tumor Cellularity
Intergenetic and Intragenetic Fusions  10% Tumor Cellularity
*Certain driver or resistance variants may be reported to lower VAFs when technically possible.
Ordering

Performed

Molecular Diagnostics

Methodology

The POP300 is a hybrid capture enrichment-based approach to create libraries, enriched for cancer-related genes, from DNA and RNA, extracted from formalin-fixed paraffin embedded (FFPE) tissue specimens.   Libraries are sequenced on the Illumina® NextSeq 550 Dx Next Generation Sequencer.  DNA-derived biomarkers include the following: single nucleotide variants (SNVs), insertions, deletions, gene amplifications, multi-nucleotide variants (MNVs), and the immunotherapy biomarkers tumor mutational burden (TMB) and microsatellite instability (MSI).  Fusions and splice variants are detected using extracted RNA.  Copy number loss is not validated at this time, and FISH is recommended to identify loss of CDKN2A and PTEN.  Immunohistochemistry is recommended to assess endometrial adenocarcinomas for mismatch repair deficiency (PMID: 36603179). Reporting will be performed using GenomOncology (GO) software.  Human genome reference 19 (hg19) is used for alignment and variant calling. 

Lists of assessed genes and limit of detection for each variant type are listed below in Tables 1 and 2, respectively.
Table 1. Genes Assessed
DNA - SNVs/Indels (322) (Total with CNV and RNA only genes = 337 genes)
ABL1 CCND1 ERBB2 FH JUN MYB PIK3R3 RICTOR TRAF7
ABL2 CCND2 ERBB3 FLCN KDM5A MYC PLCG2 RIT1 TSC1
ACVR1 CCND3 ERBB4 FLT1 KDM5C MYCL1 PMS1 RNF43 TSC2
ACVR1B CCNE1 ERCC1 FLT3 KDM6A MYCN PMS2 ROS1 U2AF1
AKT1 CD274 ERCC2 FLT4 KDR MYD88 POLD1 RPTOR VEGFA
AKT2 CD276 ERCC3 FOXA1 KEAP1 MYOD1 POLE RUNX1 VHL
AKT3 CDH1 ERCC4 FOXL2 KIT NAB2 PPARG RUNX1T1 WT1
ALK CDK12 ERCC5 FOXO1 KLF4 NBN PPM1D SDHA XRCC2
APC CDK4 ESR1 FUBP1 KRAS NF1 PPP2R1A SDHAF2 YAP1
AR CDK6 ETV6 GATA3 LATS2 NF2 PPP2R2A SDHB ZRSR2
ARAF CDK8 EWSR1 GEN1 LRP1B NFE2L2 PPP6C SDHC  
ARID1A CDKN1A EZH2 GLI1 LZTR1 NKX2-1 PREX2 SDHD  
ARID1B CDKN1B FAM175A GNA11 MAGI2 NOTCH1 PRKAR1A SETBP1  
ARID2 CDKN2A FANCA GNAQ MAP2K1 NOTCH2 PRKCI SETD2  
ASXL1 CDKN2B FANCC GNAS MAP2K2 NOTCH3 PRKDC SF3B1  
ASXL2 CDKN2C FANCD2 GPS2 MAP2K4 NOTCH4 PTCH1 SLX4  
ATM CHD4 FANCE H3F3A MAP3K1 NPM1 PTEN SMAD4  
ATR CHEK1 FANCF H3F3B MAP3K13 NRAS PTPN11 SMARCA4  
ATRX CHEK2 FANCG H3F3C MAP3K14 NRG1 PTPRD SMARCB1  
AXL CIC FANCI HGF MAP3K4 NSD1 PTPRS SMO  
B2M CREBBP FANCL HIST1H1C MAPK1 NTRK1 PTPRT SNCAIP  
BAP1 CRKL FBXW7 HIST1H3B MAPK3 NTRK2 QKI SPOP  
BARD1 CRLF2 FGF1 HIST1H3C MAX NTRK3 RAC1 SRC  
BCL2 CSF1R FGF10 HOXB13 MDC1 PALB2 RAD21 SRSF2  
BCL2L11 CSF3R FGF14 HRAS MDM2 PARP1 RAD50 STAG2  
BCL6 CTNNA1 FGF19 HSD3B1 MDM4 PAX8 RAD51 STAT3  
BCOR CTNNB1 FGF2 IDH1 MED12 PBRM1 RAD51B STK11  
BCORL1 DAXX FGF23 IDH2 MEN1 PDGFRA RAD51C SUFU  
BCR DDR2 FGF3 IGF1R MET PDGFRB RAD51D SUZ12  
BLM DICER1 FGF4 IKBKE MITF PHOX2B RAD52 TCEB1  
BMPR1A DNAJB1 FGF5 IL7R MLH1 PIK3C2B RAD54L TERT  
BRAF DNMT3A FGF6 INPP4A MPL PIK3C2G RAF1 TET1  
BRCA1 DNMT3B FGF7 INPP4B MRE11A PIK3C3 RASA1 TET2  
BRCA2 DOT1L FGF8 IRF2 MSH2 PIK3CA RB1 TFE3  
BRD4 EGFR FGF9 IRF4 MSH3 PIK3CB RBM10 TGFBR2  
BRIP1 EIF1AX FGFR1 IRS2 MSH6 PIK3CD RECQL4 TMEM127  
C11orf30 EML4 FGFR2 JAK1 MST1R PIK3CG RET TMPRSS2  
CALR EP300 FGFR3 JAK2 MTOR PIK3R1 RHEB TP53  
CBL EPCAM FGFR4 JAK3 MUTYH PIK3R2 RHOA TRAF2  
                 
CNV - All (59) Green=Unique   RNA - All (55)   Blue=Unique        
AKT2 FGF7   ABL1 JAK2        
ALK FGF8   AKT3 KDR        
AR FGF9   ALK KIF5B        
ATM FGFR1   AR KIT        
BRAF FGFR2   AXL MET        
BRCA1 FGFR3   BCL2 MLL        
BRCA2 FGFR4   BRAF MLLT3        
CCND1 JAK2   BRCA1 MSH2        
CCND3 KIT   BRCA2 MYC        
CCNE1 KRAS   CDK4 NOTCH1        
CDK4 LAMP1   CSF1R NOTCH2        
CDK6 MDM2   EGFR NOTCH3        
CHEK1 MDM4   EML4 NRG1        
CHEK2 MET   ERBB2 NTRK1        
EGFR MYC   ERG NTRK2        
ERBB2 MYCL1   ESR1 NTRK3        
ERBB3 MYCN   ETS1 PAX3        
ERCC1 NRAS   ETV1 PAX7        
ERCC2 NRG1   ETV4 PDGFRA        
ESR1 PDGFRA   ETV5 PDGFRB        
FGF1 PDGFRB   EWSR1 PIK3CA        
FGF10 PIK3CA   FGFR1 PPARG        
FGF14 PIK3CB   FGFR2 RAF1        
FGF19 PTEN   FGFR3 RET        
FGF2 RAF1   FGFR4 ROS1        
FGF23 RET   FLI1 RPS6KB1        
FGF3 RICTOR   FLT1 TMPRSS2        
FGF4 RPS6KB1   FLT3          
FGF5 TFRC              
FGF6                

Table 2. Limit of Detection for Variant Types
Variant Type Limit of Detection
Single Nucleotide Variants  5% variant allele fraction*, 10-20% Tumor Cellularity
Indels up to 15bp  5-10% variant allele fraction*, 10-20% Tumor Cellularity
Indels up to 30bp  30-80% Tumor Cellularity
Copy Number Amplifications  10% Tumor Cellularity/Fold Difference >2
Tumor Mutation Burden  20% Tumor Cellularity
Microsatellite Instability  30% Tumor Cellularity
Intergenetic and Intragenetic Fusions  10% Tumor Cellularity
*Certain driver or resistance variants may be reported to lower VAFs when technically possible.

Synonyms

  • Comprehensive Gene Panel
  • Ovarian
  • Endometrial
  • Breast Cancer
  • Prostate Cancer
  • Bladder Cancer
Result Interpretation
Administrative

CPT Codes

81455
UHC reference code:  56200053
Medicare only CPT 81479
*This test will either require prior authorization or a signed ABN
RPS Interface Information

Test Build Information

Order Code Order Name Result Code Result Name CPT
POP300 Precision Oncology Profile 300 POP300R Precision Oncology Profile 300 81455

×
Learn More Remind Me Later Dismiss